目的:通过研究恶性造血细胞中P-糖蛋白(P-gp)170的表达,为骨髓增生异常综合征(MDS)治疗提供P-gp 170低表达的体外细胞株模型.方法:用含0.1 mmol·L-1阿霉素的RPMI 1640 分别培养MDS细胞株MUTZ-1和多药耐药(MDR)红白血病细胞株K562/A02.用MTT法检测细胞的增殖抑制作用,光镜和电镜技术分别观察与阿霉素共同培养后的MUTZ-1细胞和K562/A02细胞形态和超微结构,流式细胞仪分别测定MUTZ-1细胞和K562/A02细胞P-gp 170表达水平.结果:0.1 mmol·L-1阿霉素对MUTZ-1细胞增殖呈时间依赖性抑制作用,而对K562/A02细胞的增殖没有影响;MUTZ-1细胞出现典型的凋亡形态学改变,K562/A02细胞表面呈现出许多长的微绒毛和许多微孔;K562/A02细胞与MUTZ-1细胞相比高表达P-gp 170.结论:P-gp 170在恶性造血细胞中表达有显著性差异, P-gp 170低表达的MUTZ-1细胞株可用于MDS治疗的体外研究模型, P-gp 170高表达的K562/A02细胞株可用于MDR逆转的体外研究模型.

[1] APPELBAUM F R, BARRALL J, STORB R. Bone marrow transplantation for patients with myelodysplasia.Pretreatment variables and outcome, 1990(8)
[2] de WITTE T, SUCIU S, PEETERMANS M. Intensive chemotherapy for poor prognosis myelodysplasis and secondary acute myeloid leukemia following MDS of more than 6 months duration.A pilot study by the Leukemia Cooperative Group of the European Organization for Research and Treatment in Cancer(EORTC-LCG), 1995(11)
[3] de WITTE T, van BIEZEN A, HERMANS J. Autologous bone marrow transplantation for patients with myelodysplastic syndrome(MDS) or acute myeloid leukemia following MDS.Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation, 1997(10)
[4] STEUBE K G, GIGNAC S M, HU Z B. In vitro culture studies of childhood myelodysplastic syndrome:establishment of the cell line MUTZ-1, 1997(3-4)
[5] CHEN B A, XIA G H, LI J Y. Detection of complex karyotype in a myelodysplastic syndrome cell line(MUTZ-1) by metaphase fluorescence in situ hybridization, 2006(1)
[6] MARKS D C, BELOV L, DAVEY M W. The MTT cell viability assay for cytotoxicity testing in multidrug resistant human leukemia cells. 1992(12). doi:10.1016/0145-2126(92)90114-M
[7] LIST A F, VARLIMAN J, ISSA J J. Myelodysplastic syndromes, 2004
[8] van DIJK J P, de WITTE T. Monitoring treatment efficiency in MDS at the molecular level,possibilities now and in the future. 2004(2). doi:10.1016/S0145-2126(3)00186-3
[9] KAUFMANN S H, EARNSHAW W C. Induction of apoptosis by cancer chemotherapy. 2000(1). doi:10.1006/excr.2000.4838
[10] LEE S H, ALTENBERG G A. Expression of functional multidrug-resistance protein 1 in Saccharomyces cerevisiae:effects of N-and C-terminal affinity tags. 2003(3). doi:10.1016/S0006-291X(3)01029-5
[11] ZLOH M, KAATZ G W, GIBBONS S. Inhibitors of multidrug resistance(MDR) have affinity for MDR substrates, 2004(4)
[12] WADKINS R M, ROEPE P D. Biophysical aspects of P-glycoprotein-mediated multidrug resistance, 1997